Ovulation inhibition with a combined oral contraceptive containing 20 micrograms ethinyl estradiol and 250 micrograms levonorgestrel. Serum levels of the active ingredients and FSH, LH, estradiol 17-beta and progesterone
- PMID: 294110
- DOI: 10.3109/00016347909157224
Ovulation inhibition with a combined oral contraceptive containing 20 micrograms ethinyl estradiol and 250 micrograms levonorgestrel. Serum levels of the active ingredients and FSH, LH, estradiol 17-beta and progesterone
Abstract
In order to investigate the possible ovulation inhibitory effect of a new oral contraceptive containing a combination of 20 micrograms ethinyl estradiol and 250 micrograms levonorgestrel peripheral serum from five healthy women between 17 and 24 years were analysed for FSH, LH, estradiol 17-beta and progesterone. The measurements were carried out during a control cycle before the treatment, during two treatment cycles and during a subsequent control cycle. In addition, serum levels of ethinyl estradiol and norgestrel were determined during the treatment periods. Radioimmunological methods were utilized for all the measurements. In all five women studied there was a complete inhibition of ovulation during treatment as indicated by a lack of mid-cycle LH peaks and by suppression of normal luteal phase levels of progesterone. Four out of the five women showed no biphasic estradiol pattern. During treatment the serum levels of levonorgestrel varied between 1 and 10 nmol/l while the levels of ethinyl estradiol usually were below the limit of detection for the method used (below 85 pmol/l). Post-treatment control cycles revealed a re-establishment of the ovulatory pattern in four of the five subjects.
Similar articles
-
Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol.Gynecol Obstet Invest. 1978;9(6):304-11. doi: 10.1159/000300999. Gynecol Obstet Invest. 1978. PMID: 754992
-
Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.Am J Obstet Gynecol. 1977 Sep 15;129(2):133-40. doi: 10.1016/0002-9378(77)90733-5. Am J Obstet Gynecol. 1977. PMID: 900174
-
The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis.Contraception. 1986 Nov;34(5):513-22. doi: 10.1016/0010-7824(86)90060-0. Contraception. 1986. PMID: 3102162
-
Central and peripheral parameters of the menstrual cycle under the influence of a new combined oral contraceptive.Acta Obstet Gynecol Scand Suppl. 1976;54:45-50. doi: 10.3109/00016347609156448. Acta Obstet Gynecol Scand Suppl. 1976. PMID: 788444 Review. No abstract available.
-
New delivery systems for D-norgestrel.Acta Obstet Gynecol Scand Suppl. 1976;54:35-43. doi: 10.3109/00016347609156447. Acta Obstet Gynecol Scand Suppl. 1976. PMID: 788443 Review. No abstract available.
Cited by
-
Clinical pharmacokinetics of oral contraceptive steroids.Clin Pharmacokinet. 1983 Mar-Apr;8(2):95-136. doi: 10.2165/00003088-198308020-00001. Clin Pharmacokinet. 1983. PMID: 6342899 Review. No abstract available.